DE3774274D1 - Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen. - Google Patents
Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen.Info
- Publication number
- DE3774274D1 DE3774274D1 DE8787907713T DE3774274T DE3774274D1 DE 3774274 D1 DE3774274 D1 DE 3774274D1 DE 8787907713 T DE8787907713 T DE 8787907713T DE 3774274 T DE3774274 T DE 3774274T DE 3774274 D1 DE3774274 D1 DE 3774274D1
- Authority
- DE
- Germany
- Prior art keywords
- solubilization
- proteins
- pharmaceutical compositions
- solubilizing agent
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/931,197 US4894226A (en) | 1986-11-14 | 1986-11-14 | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
| PCT/US1987/002930 WO1988003412A1 (en) | 1986-11-14 | 1987-11-10 | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3774274D1 true DE3774274D1 (de) | 1991-12-05 |
Family
ID=25460367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8787907713T Expired - Fee Related DE3774274D1 (de) | 1986-11-14 | 1987-11-10 | Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4894226A (de) |
| EP (1) | EP0305409B1 (de) |
| AT (1) | ATE68976T1 (de) |
| AU (1) | AU626518B2 (de) |
| CA (1) | CA1305051C (de) |
| DE (1) | DE3774274D1 (de) |
| WO (1) | WO1988003412A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002883A (en) * | 1987-10-30 | 1991-03-26 | Abbott Laboratories | Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents |
| US4994385A (en) * | 1987-10-30 | 1991-02-19 | Abbott Laboratories | Heterobifunctional coupling agents |
| EP0401384B1 (de) * | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemisch modifizierte granulocytenkolonie erregender faktor |
| US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
| US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| EP0540612A1 (de) * | 1990-07-20 | 1993-05-12 | Pharmacia AB | Heterobifunktionelle reagentien und konjugate mit oxaalkylen-einheiten für amphiphile brückenstrukturen |
| IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| JP2611073B2 (ja) * | 1990-07-26 | 1997-05-21 | モンサント カンパニー | 新規ポリアミンの製造方法 |
| US7449186B1 (en) | 1990-08-02 | 2008-11-11 | Fred Hutchinson Cancer Research Center | Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies |
| US5827670A (en) * | 1990-08-02 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies |
| EP0510132B1 (de) * | 1990-09-28 | 1997-05-14 | Neorx Corporation | Polymere träger zur freisetzung kovalent gebundener wirkstoffe |
| US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| DK0730470T3 (da) * | 1993-11-10 | 2002-06-03 | Enzon Inc | Forbedrede interferonpolymerkonjugater |
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5686444A (en) * | 1995-04-05 | 1997-11-11 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
| US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| PL200586B1 (pl) * | 1998-10-16 | 2009-01-30 | Biogen Idec Inc | Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów |
| AU762616B2 (en) | 1998-10-16 | 2003-07-03 | Biogen Ma Inc. | Polymer conjugates of interferon beta-1a and uses |
| ATE246202T1 (de) * | 1999-01-29 | 2003-08-15 | Hoffmann La Roche | Gcsf konjugate |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| HUP0203133A3 (en) * | 1999-10-04 | 2005-07-28 | Chiron Corp Emeryville | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| EP1935431A3 (de) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2 |
| GEP20074024B (en) | 2002-01-18 | 2007-01-10 | Biogen Idec Inc | Polyalkylene glycol comprising a radical for conjugation of biologically active compound |
| EP2174663A1 (de) | 2003-01-08 | 2010-04-14 | Novartis Vaccines and Diagnostics, Inc. | Stabilisierte wässrige Zusammensetzungen mit Gewebefaktor-Inhibitor (TFPI) oder Gewebefaktor-Inhibitorvariante |
| EP1694360B1 (de) | 2003-11-04 | 2010-08-04 | Novartis Vaccines and Diagnostics, Inc. | Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat-abstossung |
| EP2018437A2 (de) * | 2006-05-02 | 2009-01-28 | Allozyne, Inc. | Mit nicht-natürlichen aminosäuren substituierte polypeptide |
| US20080096819A1 (en) * | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
| JP5634862B2 (ja) | 2007-05-16 | 2014-12-03 | カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低粘度アントラサイクリン製剤 |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10443026B2 (en) * | 2017-12-25 | 2019-10-15 | National Tsing Hua University | Polygonal scaffold and manufacturing method thereof, and protein modulator and manufacturing method thereof |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| CN117241831A (zh) | 2021-05-07 | 2023-12-15 | 北京大学 | 水相引发氨基酸n-羧基环内酸酐聚合的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE343210B (de) * | 1967-12-20 | 1972-03-06 | Pharmacia Ab | |
| GB1479268A (en) * | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
| CH596313A5 (de) * | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
| GB1578348A (en) * | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
| JPS5688794A (en) * | 1979-12-19 | 1981-07-18 | Matsushita Electric Ind Co Ltd | Immobilization of enzyme |
| JPS57163318A (en) * | 1981-03-31 | 1982-10-07 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
| US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
| US4716120A (en) * | 1983-03-17 | 1987-12-29 | Minnesota Mining And Manufacturing Company | Stable allergenic extracts and methods |
| US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3572982D1 (en) * | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
-
1986
- 1986-11-14 US US06/931,197 patent/US4894226A/en not_active Expired - Lifetime
-
1987
- 1987-11-10 EP EP87907713A patent/EP0305409B1/de not_active Expired - Lifetime
- 1987-11-10 CA CA000551549A patent/CA1305051C/en not_active Expired - Fee Related
- 1987-11-10 AT AT87907713T patent/ATE68976T1/de active
- 1987-11-10 DE DE8787907713T patent/DE3774274D1/de not_active Expired - Fee Related
- 1987-11-10 WO PCT/US1987/002930 patent/WO1988003412A1/en active IP Right Grant
- 1987-11-10 AU AU83264/87A patent/AU626518B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU626518B2 (en) | 1992-08-06 |
| CA1305051C (en) | 1992-07-14 |
| EP0305409A1 (de) | 1989-03-08 |
| AU8326487A (en) | 1988-06-01 |
| US4894226A (en) | 1990-01-16 |
| WO1988003412A1 (en) | 1988-05-19 |
| ATE68976T1 (de) | 1991-11-15 |
| EP0305409B1 (de) | 1991-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3774274D1 (de) | Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen. | |
| DK97987A (da) | Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation | |
| DE69807679D1 (de) | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren | |
| DE69425464D1 (de) | Polysaccharidderivat und wirkstoffträger | |
| DE69128791D1 (de) | Modifizierte antikörper mit kontrollierter clearance-zeit | |
| RU94006023A (ru) | Физиологически активная композиция на основе лиофилизированных модифицированных полиалкилен оксидом комплексов белка и полипептида с циклодекстрином и способ ее получения | |
| IS3824A (is) | Protein með bundið polyethylen og aðferð til framleiðslu þess | |
| ATE369878T1 (de) | Träger-pharmaka-konjugate | |
| DK0450628T3 (da) | Saccharidmidificerede, vandopløselæige proteiner | |
| DK0953576T3 (da) | Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse | |
| BG101295A (en) | Modified human c3 proteins | |
| DE69333560D1 (de) | Transport und expression eines hybriden oberflächenproteins an der oberfläche von grampositiven bakterien | |
| PT85317A (fr) | Procede pour l:obtention d:imunotoxines par couplage d:un anticorps avec une proteine trichosanthine ou trickokirine | |
| DE69129747T2 (de) | In lösung bringen von proteinen in aktiver form | |
| DK292584A (da) | Biologisk aktive konjugater, deres fremstilling og anvendelse | |
| DE68923613T2 (de) | Superoxid-dismutaseanaloge mit neuen bindeeigenschaften. | |
| DE69513226T2 (de) | Verwendung von Azolen als Virustötende Substanzen in Lösungen von biologisch aktiven Proteinen | |
| DK0419251T3 (da) | Proteinholdige vandige opløsninger | |
| ES2170161T3 (es) | Nuevos conjugados de principios activos y proteinas. | |
| BR0014058A (pt) | Produto sólido, composição, solução aquosa de 4,4-dimetil-5a-colesta-8,14,24-triene-3(beta) -ol, e, dispositivo tendo uma concavidade | |
| PT1150716E (pt) | Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao | |
| SE9101586D0 (sv) | Modified thioredoxin and its use | |
| SU1400037A1 (ru) | Полимерный реагент для ковалентной иммобилизации биологически активных соединений, содержащих свободные аминогруппы | |
| RU94023245A (ru) | Способ приготовления препарата с постепенным высвобождением лекарственного агента, препарат с постепенным высвобождением лекарственного агента |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |